Transplantation of embryonic cell suspensions in complex treatment of patients with osteogenic sarcoma

Smikodub A.I., Radzievskaya L.V., Bendyug G.D., Glukhovskaya I.Yu.

Cell Therapy Clinic of National Medical University and "EmCell" Embryonic Tissues Center, Research Institute of Oncology and Radiology

The timely and complete chemotherapeutic treatment of many tumors may be restricted by the strong depressive effect of cytostatic preparations.

Correction of hematopoietic and immune disorders is possible through transplantation of hemopoietic cell suspensions.

In this study, we used cell suspensions of human embryonic liver for complex treatment of patients with osteogenic sarcoma and nephroblastoma. The objective of the study in was the improvement of antitumor treatment program through prevention or elimination of hematopoietic and immunological disorders.

19 children aged from 2 to 15 were observed (14 with osteogenic sarcoma, and 5 with nephroblastoma). The cryopreserved human embryonic liver cells of 7-12 weeks of gestation were transplanted. Suspensions were administered intravenously, dropwise, in volume of 1 to 4 ml; nucleated cell count was 50-30.10-6/ml; CFU-GEMM, 0.5-9.10-3.

The efficiency of transplantation of Embryonic cell suspensions (FCS) was evaluated according to patient’s condition, erythrocyte count, Hb, leukocytes, T and B-lymphocytes, and their subpopulations.

In 12 patients, cytostatic leukopenia was observed before the transplantation. After the transplantation of FCS, statistically reliable increase leukocytesof leukocyte count and absoluteamount segment-nucleated neutrophils was observed from the 10th day. Levels of Hb and erythrocytes in patients with osteogenic sarcoma was relatively stable prior to and after transplantation, and did not require any additional correction. In patients with nephroblastoma, anemia were observed prior to transplantation, and statistically reliable increase in Hb and erythrocyte values, by the 7th day from FCS transplantation. Further programmed chemotherapy in both groups of patients was carried out during 2 to 3 months, timely and complete; in so doing, blood counts remained stable.

Also observed were positive changes of cell immunity values: noted on the 7th increase of absolute and relative counts of lymphocytes (CD3), T-helpers (CD4), CD4/CD8 ratio, and NK cells was noted on the 7th day.

14th Congress of Therapeutists, 1998, p.141